Syneos Health EBITDA | SYNH

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Syneos Health

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
650 M	625 M	515 M	480 M	434 M	151 M	215 M	208 M	118 M	89.9 M	41.3 M	62.1 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
650 M	41.3 M	299 M

Quarterly EBITDA Syneos Health

2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
163 M	22 M	-	303 M	240 M	136 M	-	285 M	199 M	119 M	-	266 M	147 M	105 M	83.4 M	252 M	180 M	88 M	79.5 M	243 M	166 M	78.2 M	15 M	7.7 M	25.8 M	50.4 M	43.8 M	54.2 M	54.2 M	46.9 M	39.7 M	58.2 M	49.8 M	46.6 M	18.5 M	37.1 M	19.1 M	29 M	11.3 M	15 M	4.79 M	370 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
303 M	370 K	97 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Neuronetics STIM	-28 M	$ 2.93	1.74 %	$ 193 M	USA
Thermo Fisher Scientific TMO	8.8 B	$ 603.02	0.02 %	$ 227 B	USA
Twist Bioscience Corporation TWST	-111 M	$ 128.06	2.68 %	$ 7.66 B	USA
Senseonics Holdings SENS	-66.8 M	$ 9.33	5.97 %	$ 389 M	USA
Sotera Health Company SHC	94.9 M	$ 18.59	0.05 %	$ 5.28 B	USA
VolitionRx Limited VNRX	-20.8 M	$ 0.33	2.52 %	$ 41.5 M	Singapore
Waters Corporation WAT	359 M	$ 402.91	0.33 %	$ 24 B	USA
Exagen XGN	-12 M	$ 7.3	0.53 %	$ 157 M	USA
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
Trinity Biotech plc TRIB	-21.2 M	$ 9.06	0.64 %	$ 3.25 B	Irlanda
Accelerate Diagnostics AXDX	-33.9 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Psychemedics Corporation PMD	-793 K	-	-1.84 %	$ 15.3 M	USA
Quotient Limited QTNT	-96.6 M	-	-11.32 %	$ 1.1 M	Schweiz
Quest Diagnostics Incorporated DGX	2.13 B	$ 235.5	0.06 %	$ 26.1 B	USA
T2 Biosystems TTOO	-48.8 M	-	-39.35 %	$ 313 K	USA
Meridian Bioscience VIVO	70.9 M	-	-	$ 1.49 B	USA
Motus GI Holdings MOTS	-11.5 M	-	-34.28 %	$ 263 K	Israel
Brainsway Ltd. BWAY	1.39 M	$ 14.16	0.07 %	$ 481 M	Israel
Renalytix AI plc RNLX	-29.2 M	-	5.66 %	$ 22.7 M	Britain
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
Quidel Corporation QDEL	1.11 B	$ 13.38	0.29 %	$ 564 M	USA
Precipio PRPO	43 K	$ 27.25	0.11 %	$ 43.7 M	USA
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
Anixa Biosciences ANIX	-11.7 M	$ 2.9	0.66 %	$ 94.1 K	USA
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Biodesix BDSX	-22.2 M	$ 26.63	1.72 %	$ 201 M	USA
Biomerica BMRA	-5.24 M	$ 2.34	1.3 %	$ 6.82 M	USA
BioNano Genomics BNGO	-23.8 M	$ 1.2	1.25 %	$ 6.53 M	USA
Burning Rock Biotech Limited BNR	-33.1 M	$ 10.71	11.22 %	$ 113 M	China
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Agilent Technologies A	1.77 B	$ 146.85	0.59 %	$ 41.7 B	USA
Centogene N.V. CNTG	-29.7 M	-	-6.23 %	$ 30.6 M	Germany
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-702 M	-	0.12 %	$ 80.1 M	China
Bioventus BVS	101 M	$ 13.83	0.42 %	$ 921 M	USA
CareDx, Inc CDNA	-15.8 M	$ 50.31	2.05 %	$ 2.68 B	USA
Celcuity CELC	-172 M	$ 93.02	0.75 %	$ 4.35 B	USA
Co-Diagnostics CODX	-49.1 M	$ 1.12	2.55 %	$ 1.49 M	USA
Charles River Laboratories International CRL	428 M	$ 280.76	0.54 %	$ 13.9 B	USA
Castle Biosciences CSTL	-2.04 M	$ 32.76	1.03 %	$ 950 M	USA
Danaher Corporation DHR	5.44 B	$ 205.23	0.53 %	$ 146 B	USA
DarioHealth Corp. DRIO	-36.3 M	$ 7.03	3.72 %	$ 28 M	Israel
DexCom DXCM	1.16 B	$ 84.53	0.02 %	$ 33 B	USA
Fulgent Genetics FLGT	-67 M	$ 20.2	2.38 %	$ 622 M	USA